Nelson and Masel (1) present a general mathematical model that describes effects of somatic cell changes on aging bounded by juxtaposed loss of cellular vigor and uncontrolled cell growth. The formulation reflects observations on a wide range of multicellular organisms, from Caenorhabditis elegans to Homo sapiens, incorporating the Picard-Lindelof and Frobenius theorems, and using the Price equation to describe general effects of intercellular competition over organismal lifespan. The authors propose further comparisons: across taxa, among individuals of the same population, among tissues of the same individual, and across developmental time.
Here we document parallel patterns bounded by vigor vs. proliferation developmentally mediated above intercellular levels. Our constructive perspective includes and extends research (2) on a unique human subpopulation defined by the common developmental genetic signature of Down syndrome (DS), trisomy-21. Phenotypically, DS shows decreases in both vigor and some cancer-disposing cellular proliferation. After age 35, DS mortality rates double every 6.4 y vs. 9.6 y for those unaffected, with DS individuals experiencing more rapid senescence and reduced levels of muscular strength. However, they are much less likely to experience certain malignancies (3). Large-scale studies report only half as many solid tumors as expected (4). Among 54.1 million European patients, there were no identified cases of neuroblastoma-affected DS children, versus five cases expected (4). In the Danish Cytogenetic and Cancer Registries no DS breast cancer cases were identified, against seven cases expected (4). A French registry spanning 24 y included five DS breast cancer cases, with 69 cases expected (4). In contrast to inferred protective effect of an extra copy of chromosome 21 reducing incidence of solid tumors in DS individuals, the presence of trisomy 21 is considered one of the most notable risk factors for the development of acute leukemias, with DS children having 10-to 20-fold increased risk of developing acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) compared with non-DS children. Protective effects in solid tumors and enhanced risks in lymphomas both involve expression of specific genetic loci (4). The COL18A1 locus on chromosome 21 encodes for the antiangiogenic agent endostatin, which inhibits solid tumor development. Similarly, DSCR-1 (Down syndrome critical region 1) blocks blood vessel formation and tumor progression, and the ETS 2 oncogene inhibits development of intestinal tumors. In hyperdiploid ALL, blast cells uniformly contain three to four copies of chromosome 21, while the TEL-AML1 t(12;21)(p13;q22) translocation involves the AML1 oncogene on chromosome 21 (4). Similar trade-offs between frailty and proliferation mark Klinefelter syndrome (KS: 47,XXY), with reduced muscle strength and bone mineral density (5); ≤ 5 y of lifespan and 50% increased mortality reflect death increased chiefly by cerebrovascular diseases. Breast carcinomas also are greatly in excess of expected numbers for men, matching expectations for women (6) . Solid tumor risk in KS was one-third lower, with standard incidence ratio = 0.66, but risk of hematological malignancy increased, with standard incidence ratio = 2.72 (7).
In DS and KS, developmental patterns appear copy-mediated at tissue and organismic levels; illustratively, increased incidence of 47,XXY in males with systemic erythematosus lupus shows a gene-dosage effect for the X chromosome (8) . Higher-order interactions seen in DS and KS do not contradict the intercellular competition model (1), but rather extend its generality of life-history trade-off. Moreover, while aging of multicellular organisms may be inevitable, its tempo can respond with remarkable plasticity to environmental effects. Survival of people with KS has increased modestly through avoidance of institutionalization with its three to five times higher deaths from respiratory disease, but that of DS has improved >fourfold, from an average of 12 y in the 1940s (9) to about 60 y currently (10), with gains approximating half a century of additional life resulting from noninstitutionalized social engagement as well as improved medical care. Although inexorable, the appointment in Samarra can be deferred. 
